Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis

Simon K., O'Reilly E., Munger K., S Finerty, AJ Morgan, Ascherio A.

Research output: Contribution to journalArticle (Academic Journal)peer-review

13 Citations (Scopus)

Abstract

Previous infection with Epstein-Barr virus (EBV) and infectious mononucleosis (IM) are established MS risk factors, and elevated serum titers of anti-EBV nuclear antigen antibodies (anti-EBNA) in healthy adults are strongly correlated with future MS risk. In this prospective study, we sought to investigate the association between EBV neutralizing antibodies and MS risk. Our primary hypothesis was that high levels of neutralizing antibodies would be associated with decreased MS risk. Contrary to what we expected, MS risk tended to be higher in individuals with high titers of neutralizing antibodies compared to those with low titers (RR=2.1, 95% CI:0.9, 4.8). This association was attenuated after adjustment for anti-EBNA1 IgG Ab titers (RR=1.3, 95% CI: 0.5, 3.2). This preliminary finding is limited by the small number of cases and warrants further study in a larger population.
Translated title of the contributionEpstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis
Original languageEnglish
Number of pages3
JournalMultiple Sclerosis Journal
Publication statusPublished - Jan 2012

Bibliographical note

Publisher: Sage

Fingerprint

Dive into the research topics of 'Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis'. Together they form a unique fingerprint.

Cite this